Cargando…

Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes

The aim of this study was to evaluate which administration timing of valsartan provides satisfactory blood pressure (BP) control, once daily in the morning, once daily in the evening, or twice daily in total 160 mg. Hypertensive patients with mild-to-moderate diabetic nephropathy were enrolled, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Katsunori, Aizawa, Yoshifusa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673599/
https://www.ncbi.nlm.nih.gov/pubmed/21166600
http://dx.doi.org/10.3109/10641963.2010.503306
_version_ 1782404771727015936
author Suzuki, Katsunori
Aizawa, Yoshifusa
author_facet Suzuki, Katsunori
Aizawa, Yoshifusa
author_sort Suzuki, Katsunori
collection PubMed
description The aim of this study was to evaluate which administration timing of valsartan provides satisfactory blood pressure (BP) control, once daily in the morning, once daily in the evening, or twice daily in total 160 mg. Hypertensive patients with mild-to-moderate diabetic nephropathy were enrolled, but those with more than three anti-hypertensive agents, renal insufficiency (serum creatinine ≥ 3 mg/ dL), or hepatic insufficiency were excluded. They were randomized to receive valsartan 160mg once daily in the morning, valsartan 160 mg once daily in the evening, or valsartan 80 mg twice daily for 12 weeks according to a three-period crossover design. Office blood pressure (OBP), home blood pressure (HBP) self-measured by patients, and urinary albumin excretion adjusted by creatinine excretion (UAE) were measured every 12 weeks. In 34 patients, (male: 18, mean age: 57.5 ± 10.3), valsartan with ether all administration timing demonstrated significant reductions in OBP and HBP compared to baseline: valsartan 160 mg once daily in the morning: −12.2/−9.5 mmHg (p < 0.01); valsartan 160 mg once daily in the evening: −14.2/−10.3 mmHg (p < 0.01); valsartan 80 mg twice daily: −15.0/−10.2 mmHg (p < 0.01) There was no statistically significant differences in a decrease in OBP and HBP, and reduction of UAE among three administration timing. In conclusion, these data indicate that the efficacy on BP-lowering does not depend on administration timing of valsartan in patients with diabetic nephropathy.
format Online
Article
Text
id pubmed-4673599
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-46735992015-12-15 Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes Suzuki, Katsunori Aizawa, Yoshifusa Clin Exp Hypertens Regular Articles The aim of this study was to evaluate which administration timing of valsartan provides satisfactory blood pressure (BP) control, once daily in the morning, once daily in the evening, or twice daily in total 160 mg. Hypertensive patients with mild-to-moderate diabetic nephropathy were enrolled, but those with more than three anti-hypertensive agents, renal insufficiency (serum creatinine ≥ 3 mg/ dL), or hepatic insufficiency were excluded. They were randomized to receive valsartan 160mg once daily in the morning, valsartan 160 mg once daily in the evening, or valsartan 80 mg twice daily for 12 weeks according to a three-period crossover design. Office blood pressure (OBP), home blood pressure (HBP) self-measured by patients, and urinary albumin excretion adjusted by creatinine excretion (UAE) were measured every 12 weeks. In 34 patients, (male: 18, mean age: 57.5 ± 10.3), valsartan with ether all administration timing demonstrated significant reductions in OBP and HBP compared to baseline: valsartan 160 mg once daily in the morning: −12.2/−9.5 mmHg (p < 0.01); valsartan 160 mg once daily in the evening: −14.2/−10.3 mmHg (p < 0.01); valsartan 80 mg twice daily: −15.0/−10.2 mmHg (p < 0.01) There was no statistically significant differences in a decrease in OBP and HBP, and reduction of UAE among three administration timing. In conclusion, these data indicate that the efficacy on BP-lowering does not depend on administration timing of valsartan in patients with diabetic nephropathy. Taylor & Francis 2011-02-01 2010-12-19 /pmc/articles/PMC4673599/ /pubmed/21166600 http://dx.doi.org/10.3109/10641963.2010.503306 Text en © 2011 The Author(s). Published by Taylor & Francis. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Regular Articles
Suzuki, Katsunori
Aizawa, Yoshifusa
Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes
title Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes
title_full Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes
title_fullStr Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes
title_full_unstemmed Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes
title_short Evaluation of Dosing Time-Related Anti-Hypertensive Efficacy of Valsartan in Patients with Type 2 Diabetes
title_sort evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes
topic Regular Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673599/
https://www.ncbi.nlm.nih.gov/pubmed/21166600
http://dx.doi.org/10.3109/10641963.2010.503306
work_keys_str_mv AT suzukikatsunori evaluationofdosingtimerelatedantihypertensiveefficacyofvalsartaninpatientswithtype2diabetes
AT aizawayoshifusa evaluationofdosingtimerelatedantihypertensiveefficacyofvalsartaninpatientswithtype2diabetes